Skip links

Latest

Make well informed decisions, quickly through industry leading process simulation, economic analysis software.

Get in touch
Continuous processing: Part 3

Continuous processing: Part 3

What’s happening in downstream processing? Welcome to the latest instalment of our continuous processing blog series. In Part 2 we considered the overall cost picture of the economics of continuous processing and touched upon the impact of perfusion versus fed batch – a theme we

Continuous processing: Part 2

Continuous processing: Part 2

Some biopharma companies have been running perfusion bioreactors in a continuous mode for several decades. The choice of whether to use continuous or not was dictated by the product, and little has been published on the economics of continuous perfusion processes. In today’s blog we

Continuous processing: Part 1

Continuous processing: Part 1

Over the next couple of blogs, we’d like to take a closer look at continuous processing, including the challenges associated with it, focusing on the cost drivers for perfusion versus fed batch, and the potential for continuous downstream processing. Continuous processing has increasingly been seen

Biopharm unveils BioSolve Process 5

Biopharm unveils BioSolve Process 5

Software demonstrates how shift from stainless steel to continuous processing technology potentially reduces CAPEX by over 75% and CoG below $20g/L Biopharm, the bioprocess analysis software developer, today announced the introduction of BioSolve Process 5, the latest version of the company’s flagship software tool. The

Mab Manufacturing Today & Tomorrow

Mab Manufacturing Today & Tomorrow

In conjunction with today’s launch of BioSolve Process 5, we have developed a whitepaper that demonstrates the significant savings that can be achieved by biopharma innovators in monoclonal antibody manufacture. The study used BioSolve Process to evaluate three different development scenarios: Current stainless steel technology